Samuel Rosner, Augusto Valdivia, Hui Jing Hoe, Joseph C Murray, Benjamin Levy, Enriqueta Felip, Benjamin J Solomon
{"title":"Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.","authors":"Samuel Rosner, Augusto Valdivia, Hui Jing Hoe, Joseph C Murray, Benjamin Levy, Enriqueta Felip, Benjamin J Solomon","doi":"10.1200/EDBK_389968","DOIUrl":null,"url":null,"abstract":"<p><p>Antibody Drug Conjugates (ADCs) are a novel class of therapeutic that structurally comprise an antibody directed at a tumor epitope connected via a linker to a cytotoxic payload that have shown significant antitumor activity across a range of malignancies including lung cancer. In this article we review the pharmacology of ADCs, describe results of trials with ADCs directed at targets in lung cancer including Trophoblast cell-surface antigen 2(TROP2), HER3, MET, Carcinoembryonic antigen-related cell adhesion molecular 5(CECAM-5) and HER2. Trastuzumab Deruxtecan (also known as DS-8201a or T-DXd) an ADC directed at HER2 recently became the first ADC to receive FDA approval in lung cancer, on the basis of its activity in tumors with HER2 mutations, demonstrated in the Destiny-Lung01 and Lung02 trials.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/EDBK_389968","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
Abstract
Antibody Drug Conjugates (ADCs) are a novel class of therapeutic that structurally comprise an antibody directed at a tumor epitope connected via a linker to a cytotoxic payload that have shown significant antitumor activity across a range of malignancies including lung cancer. In this article we review the pharmacology of ADCs, describe results of trials with ADCs directed at targets in lung cancer including Trophoblast cell-surface antigen 2(TROP2), HER3, MET, Carcinoembryonic antigen-related cell adhesion molecular 5(CECAM-5) and HER2. Trastuzumab Deruxtecan (also known as DS-8201a or T-DXd) an ADC directed at HER2 recently became the first ADC to receive FDA approval in lung cancer, on the basis of its activity in tumors with HER2 mutations, demonstrated in the Destiny-Lung01 and Lung02 trials.
抗体药物偶联物(Antibody Drug Conjugates, adc)是一类新型的治疗药物，它在结构上包含一种靶向肿瘤表位的抗体，通过连接物连接到细胞毒性有效载荷，这种有效载荷在包括肺癌在内的一系列恶性肿瘤中显示出显著的抗肿瘤活性。在本文中，我们回顾了adc的药理学，描述了adc针对肺癌靶点的试验结果，包括滋养细胞表面抗原2(TROP2)、HER3、MET、癌胚抗原相关细胞粘附分子5(CECAM-5)和HER2。Trastuzumab Deruxtecan(也称为DS-8201a或T-DXd)是一种针对HER2的ADC，最近成为第一个获得FDA批准用于肺癌的ADC，基于其在HER2突变肿瘤中的活性，在Destiny-Lung01和Lung02试验中得到证实。
期刊介绍：
The Ed Book is a National Library of Medicine–indexed collection of articles written by ASCO Annual Meeting faculty and invited leaders in oncology. Ed Book was launched in 1985 to highlight standards of care and inspire future therapeutic possibilities in oncology. Published annually, each volume highlights the most compelling research and developments across the multidisciplinary fields of oncology and serves as an enduring scholarly resource for all members of the cancer care team long after the Meeting concludes. These articles address issues in the following areas, among others: Immuno-oncology, Surgical, radiation, and medical oncology, Clinical informatics and quality of care, Global health, Survivorship.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
